When was Xunsheng Biomedical Research founded?

Xunsheng Biomedical Research was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Xunsheng Biomedical Research located?

Xunsheng Biomedical Research is headquartered in Liaoyuan, China.

Is Xunsheng Biomedical Research a funded company?

Xunsheng Biomedical Research is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jun 09, 2022.

When was the latest funding round of Xunsheng Biomedical Research?

Xunsheng Biomedical Research's latest funding was a $***** Seed round on Jun 09, 2022, with participation from 0 investor. Its primary sector is Oncology. In China, the Oncology sector has seen $354M in funding in 2026 to date.

Where does Xunsheng Biomedical Research rank among its competitors?

Xunsheng Biomedical Research ranks 37th amongst 39 active competitors, of which 13 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Breezebio, which secured $60M in Feb, 2026.

Who are the top competitors of Xunsheng Biomedical Research?

Xunsheng Biomedical Research's top competitors include CureVac, Dyne Therapeutics and Scancell. Among them, Breezebio secured the most recent funding round in February, 2026.

Xunsheng Biomedical Research - 2026 Company Profile, Funding & Competitors

Xunsheng Biomedical Research is a seed company based in Liaoyuan (China), founded in 2021. It operates as a Developer of immunotherapies for the treatment of cancer. Xunsheng Biomedical Research has raised an undisclosed amount in funding. The company has 39 active competitors, including 13 funded and 8 that have exited. Its top competitors include companies like CureVac, Dyne Therapeutics and Scancell.

Company Details

Developer of immunotherapies for the treatment of cancer. The company focuses on developing immunotherapy products, including cell immunotherapy and tumor therapeutic vaccines, such as cervical cancer.

Website: www.aeonvital.com
Email ID: *****@aeonvital.com
Phone Number: +86 **********

Key Metrics

Founded Year

2021

Location

Liaoyuan, China

Stage

Seed

Latest Funding Round

Seed, Jun 09, 2022, $*****

Ranked

37^th among 39 active competitors

Similar Companies

CureVac & 48 more

View Xunsheng Biomedical Research's full profile

Xunsheng Biomedical Research has raised funding over 1 round.

Here is the list of recent funding rounds of Xunsheng Biomedical Research:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 09, 2022	7522384	Seed	1691749	8041947	9321884	8010475

Access funding benchmarks and valuations. Sign up today!

View details of Xunsheng Biomedical Research's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Xunsheng Biomedical Research include CureVac, Dyne Therapeutics and Scancell. Here is the list of Top 10 competitors of Xunsheng Biomedical Research, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates Foundation & 16 others	67/100
2nd	Dyne Therapeutics 2017, Cambridge (United States), Public	Developer of nucleic acid therapies for rare diseases	$166M	Logos, Wellington & 5 others	66/100
3rd	Scancell 1997, Nottingham (United Kingdom), Public	Developer of therapeutic vaccines for the treatment of cancer and infectious diseases	$5.84M	Redmile Group, Calculus Capital & 6 others	60/100
4th	Immunomic Therapeutics 2005, Rockville (United States), Series B	Vaccines for allergy, cancer and infectious disease.	$104M	HLB, Defense.gov & 7 others	57/100
5th	Novavax 1987, Gaithersburg (United States), Public	Developer of novel vaccines for the treatment of infectious diseases	-	RA Capital Management, Foresite Capital & 13 others	54/100
6th	PopVax 2021, Hyderabad (India), Funding Raised	Developer of mRNA platform for vaccines and therapeutics	-	Medical Countermeasures, Gates Foundation	50/100
7th	Breezebio 2021, San Francisco (United States), Series B	Developer of targeted genetic medicines using hydrophilic polymer nanoparticles for delivery	$110M	Yuanta Investment, DSC Investment & 29 others	46/100
8th	Codagenix 2011, Stony Brook (United States), Series B	Developer of live-attenuated viral vaccines using proprietary SAVE technology	$47.1M	Topspin Fund, Euclidean Capital & 9 others	45/100
9th	Chimeron 2015, Philadelphia (United States), Series A	Developer of nucleic acid-based therapeutic solutions for treating cancer	$15.2M	Dreavent, Accelerate NY Seed Fund	45/100
10th	Immuno Cure 2015, Sha Tin (China), Series A	Developer of DNA vaccines and immunotherapies for multiple disorders	$12M	AEF Greater Bay Area Fund	44/100
37th	Xunsheng Biomedical Research 2021, Liaoyuan (China), Seed	Developer of immunotherapies for the treatment of cancer	-	-	24/100